FDA Approval Alert: The Need-to-Know | Vorasidenib in Grade 2 IDH+ Astrocytoma/Oligodendroglioma

In August 2024, the FDA approved vorasidenib (Voranigo) for patients 12 years and older with grade 2 astrocytoma or oligodendroglioma harboring IDH1 or IDH2 mutations.

Phase 3 data from the INDIGO trial support the FDA approval of vorasidenib for select patients with grade 2 astrocytoma or oligodendroglioma.
FDA Approves Vorasidenib in IDH+ Astrocytoma/Oligodendroglioma
Article
Aug 6, 2024 8:27 PM
Phase 3 data from the INDIGO trial support the FDA approval of vorasidenib for select patients with grade 2 astrocytoma or oligodendroglioma.